Plain-English translation of NCT07195825 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing BBM-P002, a new gene therapy treatment for Parkinson's disease. Instead of a pill, the medication is injected directly into specific areas of the brain during a surgical procedure. Researchers want to see if this one-time treatment is safe and well-tolerated, and whether it helps reduce Parkinson's symptoms over the next 5 years.
Current Parkinson's treatments like levodopa help many people, but their effects can wear off over time. This trial explores whether delivering therapeutic genes directly to the brain could offer a longer-lasting or more effective treatment option for people with advanced Parkinson's disease.
You likely qualify if…
You likely don't qualify if…
You would come to the hospital for one surgical procedure where the medication is injected into specific areas of your brain. After the injection, you'll be closely monitored for safety and symptom changes through regular clinic visits over 52 weeks, with follow-up appointments continuing for up to 5 years. You'll also be asked to keep a diary of your symptoms and how you're feeling, and may have blood tests, MRI scans, and questionnaires to assess the treatment's effects.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Shanghai Xinzhi BioMed Co., Ltd.
Enrollment target
~18 participants
Started
December 2025
Primary completion
December 2027
Age range
40 Years – 70 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wenshu Luo, Ph.D
Ruijin Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.